Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could ease sudden back pain in days

NCT ID NCT06511765

Symptom relief Sponsor: Elsan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an injection of numbing medicine and steroids into the back muscles can quickly relieve sudden low back pain. About 40 adults with pain lasting less than a week will receive either the injection or a placebo. The goal is to see if the treatment reduces pain during activity over the first four days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with lumbago lasting less than 7 days despite analgesic / NSAID treatment. 2. Patient with NS pain \> 6 3. Patient with Oswestry score \> or equal to 30 4. Patient informed of the trial and having signed the informed consent form prior to any trial-specific procedure, 5. Patient willing and able to undergo all planned examinations and procedures in compliance with the clinical trial protocol, 6. Patient affiliated to a social security or any health insurance. Exclusion Criteria: 1. Presence of "red flag" (non-disc lumbago): * Motor deficit or signs of horsetail irritation * Inflammatory pain waking up in the 2nd half of the night * Tumoral context * Infectious context or fever * Altered general condition * Traumatic context * Osteoporotic context 2. Risk of infection 3. Patient with poor local skin condition 4. Patient on AVK or anti-Xa anticoagulation, or bleeding disorder (antiaggregants authorized) 5. Patients with hypersensitivity to Ropivacaine or any of its excipients: Sodium chloride, hydrochloric acid sodium hydroxide 6. Patient with sciatica 7. Patient with chronic respiratory insufficiency 8. Patient with cardiac rhythm disorders 9. Pregnant or breastfeeding woman or woman refusing effective contraception 10. Patient deprived of liberty or under legal protection (guardianship or curator) 11. Patient participating in another clinical research protocol involving a drug or medical device 12. Patient unable to follow the protocol, as judged by the investigator 13. Patient refusing to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lumbago are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Low Back Pain Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lumbago

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Santé Atlantique ELSAN

    RECRUITING

    Saint-Herblain, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.